Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cem Gabay

Showing results (61-70 of 259) with videos related to

Pageof 26
Sort By:
Swiss Medical Weekly|December 13, 2017
The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritisGregory Fleury, Sylvano Mania, Didier Hannouche, et al.
Arthritis Care & Research|November 11, 2022
Reporting and Representativeness of Race, Ethnicity, and Socioeconomic Status in Systemic Sclerosis Randomized Trials: An Observational StudyEdouard Chaix, Denis Mongin, Cem Gabay, et al.
Seminars in Arthritis and Rheumatism|October 7, 2006
Systemic rheumatoid vasculitis: a reviewMarcia S Genta, Robert M Genta, Cem Gabay
Therapeutics and Clinical Risk Management|May 14, 2008
A systematic review of infliximab in the treatment of early rheumatoid arthritisSophie Martin Du Pan, Cem Gabay, Axel Finckh
Revue Medicale Suisse|March 8, 2018
[Management of septic arthritis]Anne-Cécile Debrach, Ilias Lazarou, Cem Gabay, et al.
Journal of Leukocyte Biology|November 22, 2015
SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotypeMaria Stella Lombardi, Corine Gilliéron, Damien Dietrich, et al.
Rheumatology (Oxford, England)|January 25, 2011
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort studyDiego Kyburz, Cem Gabay, Beat A Michel, et al.
Cytokine|March 24, 2004
Production of intracellular IL-1alpha, IL-1beta, and IL-1Ra isoforms by activated human dermal and synovial fibroblasts: phenotypic differences between human dermal and synovial fibroblastsMichel Maret, Rachel Chicheportiche, Jean-Michel Dayer, et al.
Best Practice & Research. Clinical Rheumatology|September 19, 2006
Is IL-1 a good therapeutic target in the treatment of arthritis?Danielle Burger, Jean-Michel Dayer, Gaby Palmer, et al.
Rheumatology International|May 17, 2007
Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritisPaul Emery, Cem Gabay, Maarten Kraan, et al.
Pageof 26

Showing results (61-70 of 259) with videos related to

Sort By:
Pageof 26
Swiss Medical Weekly|December 13, 2017
The perioperative use of synthetic and biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritisGregory Fleury, Sylvano Mania, Didier Hannouche, et al.
Arthritis Care & Research|November 11, 2022
Reporting and Representativeness of Race, Ethnicity, and Socioeconomic Status in Systemic Sclerosis Randomized Trials: An Observational StudyEdouard Chaix, Denis Mongin, Cem Gabay, et al.
Seminars in Arthritis and Rheumatism|October 7, 2006
Systemic rheumatoid vasculitis: a reviewMarcia S Genta, Robert M Genta, Cem Gabay
Therapeutics and Clinical Risk Management|May 14, 2008
A systematic review of infliximab in the treatment of early rheumatoid arthritisSophie Martin Du Pan, Cem Gabay, Axel Finckh
Revue Medicale Suisse|March 8, 2018
[Management of septic arthritis]Anne-Cécile Debrach, Ilias Lazarou, Cem Gabay, et al.
Journal of Leukocyte Biology|November 22, 2015
SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an anti-inflammatory phenotypeMaria Stella Lombardi, Corine Gilliéron, Damien Dietrich, et al.
Rheumatology (Oxford, England)|January 25, 2011
The long-term impact of early treatment of rheumatoid arthritis on radiographic progression: a population-based cohort studyDiego Kyburz, Cem Gabay, Beat A Michel, et al.
Cytokine|March 24, 2004
Production of intracellular IL-1alpha, IL-1beta, and IL-1Ra isoforms by activated human dermal and synovial fibroblasts: phenotypic differences between human dermal and synovial fibroblastsMichel Maret, Rachel Chicheportiche, Jean-Michel Dayer, et al.
Best Practice & Research. Clinical Rheumatology|September 19, 2006
Is IL-1 a good therapeutic target in the treatment of arthritis?Danielle Burger, Jean-Michel Dayer, Gaby Palmer, et al.
Rheumatology International|May 17, 2007
Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritisPaul Emery, Cem Gabay, Maarten Kraan, et al.
Pageof 26